involved in blood pressure regulation [14] . The increase in blood pressure develops over time and is associated with reduced circumference and an increased media-tolumen ratio of resistance arteries, indicating inward remodeling [14] . Probably, this change in arterial structure, due to lack of GPER1, takes time to develop, explaining why high blood pressure is observed in old but not young animals. Acute intravenous infusion of the GPER1 agonist G-1 has been reported to cause a slight reduction in mean arterial pressure in normotensive male rats [15] . Furthermore, chronic infusion of G-1 via an osmotic minipump over a 2-week period lowers mean arterial pressure in hypertensive and ovariectomized female mRen2.Lewis rats [16] , further strengthening the idea that GPER1 is involved in the regulation of blood pressure. G-1, at 1-10 μ M , relaxes agonist-induced force in different vascular preparations such as rat mesenteric arteries, rat aorta, rat carotid arteries and human internal mammary arteries [15] [16] [17] , suggesting that GPER1 regulates vascular contractility. However, this receptor also seems to play a role in vascular smooth muscle and endothelial cell proliferation, which is inhibited by G-1 in the micromolar concentration range [15, 18] . Although activation of vascular GPER1 is supposed to regulate vascular contractility as well as vascular smooth muscle and endothelial cell proliferation, very little is known about the molecular mechanisms behind these effects [15, 18] . Here, we hypothesize that the mechanism behind reported GPER1 effects in the cardiovascular system involves regulation of vascular smooth muscle cell Ca 2+ handling.
Changes in intracellular Ca
2+ levels may have a broad impact on vascular smooth muscle cell function, since Ca 2+ plays an important role in regulating contractility, apoptosis, transport as well as proliferation [19] . Oscillations in the intracellular Ca 2+ concentration in vascular smooth muscle cells are thought to depend on both intracellular Ca 2+ release and inflow of Ca 2+ from the extracellular space [20, 21] . Ca 2+ oscillations may regulate vascular reactivity by inducing rhythmical contractions [20] .
In order to assess the possible involvement of GPER1 in the regulation of vascular smooth muscle cell Ca 2+ homeostasis, we investigate here the effects of the GPER1-selective agonist G-1 on intracellular Ca 2+ levels in rat aortic smooth muscle A7r5 cells. Interestingly, we show that G-1 acutely reduces Ca 2+ spike activity in A7r5 cells expressing GPER1 in a similar manner as the conventional voltage-sensitive L-type Ca 2+ channel blocker nifedipine, suggesting a role for this mechanism in GPER1-mediated control of blood pressure.
Materials and Methods

Cells and Cell Culture
The vascular smooth muscle cell line A7r5 was from American Type Tissue Culture Collection (Manassas, Va., USA) and cultured in accordance with their recommendations. A7r5 is a wellcharacterized rat embryonic aortic smooth muscle cell line. A7r5 cells develop spontaneous and synchronous Ca 2+ spikes, and the cells respond to agonist stimulation via a rise in intracellular Ca 2+ concentration and increased Ca 2+ spike activity, as demonstrated by Byron and Taylor [22] . The Ca 2+ spikes depend on cell-cell communication and inflow of extracellular Ca 2+ through voltagesensitive L-type Ca 2+ channels [22] . Before experiments, normal culture medium was replaced with phenol red-free and fetal calf serum-free culture medium for 24 h to make the cells quiescent and to remove the estrogen-like activity of phenol red. Experiments were performed in confluent A7r5 cells.
Reverse Transcription PCR
Total RNA was extracted and purified using an RNeasy mini kit (Qiagen, Valencia, Calif., USA). RNA concentration and purity was assessed at 260/280 nm in a NanoDrop ND-100 spectrophotometer (NanoDrop Technologies Inc., Wilmington, Del., USA). cDNA was generated and mRNA for GPER1 determined as previously described by Mårtensson et al. [14] . Reverse transcriptase (RT)-negative controls were included to exclude the presence of contaminating genomic DNA. The sequences of GPER1 primers were: GATCGTTAGATTAACAGAGCAG (forward) and CCTGGGAGCCTGTTAGTCTCAG (reverse). This primer pair produces a GPER1-specific product [14] . Moreover, we have previously confirmed, using the same GPER1 primer pairs, that RAW264.7 cells, regarded as a positive control for GPER1, express a strong band at the correct predicted size [18] . For quantitative real-time PCR, the RNA samples were subjected to one-step quantitative real-time PCR measurements using a QuantiFast SYBR Green RT-PCR kit (Qiagen) and QuantiTect primer assays (Qiagen) on a Step One Plus real-time thermal cycler (Applied Biosystems, Foster City, Calif., USA). Each sample was analyzed in duplicate. Gene expression was calculated using the ΔC T method as described by Pfaffl [23] . The RNA samples were used for quantitative RT-PCR measurements applying glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping reference gene. The PCR primers (QuantiTect primer assays) for GPER1 (Rn_Gper_1_ SG), CACNA 1c (Rn_Cacna1c_2_SG) and GAPDH (Rn_Gapd_1_ SG) were purchased from Qiagen.
Determination of Intracellular Ca 2+ Concentration
To determine intracellular Ca 2+ concentration, cells were cultured on glass bottom cell culture Petri dishes (MatTek, Ashland, Mass., USA). After reaching confluence, the cells were washed with N-2-hydroxyethylpiperazine-N ′ -2-ethanesulfonic acid (HEPES)-buffered physiological salt solution of the following composition (in m M ): NaCl 135.5, KCl 5.9, CaCl 2 2.5, MgCl 2 1.2, HEPES 11.6 and glucose 11.5. The cells were incubated with the Ca 2+ -sensitive fluorescent dye Fluo-4-AM (3 μ M ; Invitrogen, Carlsbad, Calif., USA) for 40 min at room temperature and then washed carefully. During the Ca 2+ measurements, the cells were incubated in HEPES-buffered physiological salt solution containing 2.5 m M Ca 2+ . Fluorescence was recorded using a laser scanning confocal microscope (LSM 5 PASCAL; Carl Zeiss AG, Göttingen, Germany).
The excitation wavelength was 488 nm and the emission wavelength 505 nm. A summarized fluorescence signal was collected from all cells (about 500 cells) within the visual field at ×100 magnification. The confocal pinhole setting was identical for all experiments. For each dish, Ca 2+ spike activity in the presence of G-1 and G-15 was compared with that observed in the presence of vehicle prior to inclusion of the drugs, i.e. in each cell preparation, a paired comparison of Ca 2+ spike activity was performed. The frequency of the Ca 2+ spikes and their mean amplitudes were determined over a 10-min time period directly upon addition of G-1 and G-15. Spikes were generally well resolved, and their frequency and amplitude easy to determine unambiguously (please see original recordings in the figures).
Drugs G-1 was purchased from Cayman Chemical, Ann Arbor, Mich., USA. G-15 was kindly supplied by Prof. Roger Olsson, Lund University. 17β-estradiol (E 2 ) was purchased from Sigma Chemicals, St. Louis, Mo., USA. G-1, G-15 and E 2 were dissolved in DMSO. The thromboxane A 2 analogue U46619 (Tocris Bioscience, Bristol, UK) and the L-type Ca 2+ channel blocker nifedipine (Sigma Chemicals) were dissolved in DMSO. Controls received DMSO as vehicle. The final concentration of DMSO was 0.1-0.3%.
Statistics
Values are presented as means ± SEM. Statistical significance was calculated using ANOVA and Student's two-tailed t test for paired comparisons with Bonferroni correction for post hoc analysis as appropriate. Values of p < 0.05 were regarded to denote statistical significance. fig. 2 b-d) . Lower concentrations of G-1 (300 n M ) reduced Ca 2+ spike amplitude but had no effect on Ca 2+ spike frequency ( fig. 2 c, d ). Vehicle control (0.1% DMSO) had no effect on Ca 2+ spike activity ( fig. 2 a) . The spontaneous Ca 2+ spike frequency was 2.9 ± 0.4 per minute (n = 13) before inclusion of 0.1% DMSO compared to 3.1 ± 0.5 per minute (n = 13) in the presence of DMSO. In fact, 1 μ M G-1 made the Ca 2+ spikes disappear totally within 200-300 s in 11 of 17 experiments, i.e. in about 65% of the experiments ( fig. 2 b-d) .
Results
G-1 Reduces Ca
The G-1-induced attenuation of Ca 2+ spike activity is reversible since the Ca 2+ spikes reappeared after washout of G-1 (data not shown). The voltage-sensitive L-type Ca 2+ channel blocker nifedipine (100 n M ) fully inhibited Ca 2+ spike activity within 200-300 s ( fig. 3 ) , showing that nifedipine acts similar to G-1. Stimulation with the thromboxane A 2 analogue U46619 (1 μ M ) increased the intracellular Ca 2+ plateau level and Ca 2+ spike frequency ( fig. 4 ) . Addition of G-1 (1 μ M ) to U46619-stimulated cells markedly reduced the Ca 2+ spike activity but had no effect on the plateau level of the U46619-evoked Ca 2+ response ( fig. 4 ) . The U46619-evoked increase in Ca 2+ spike frequency was completely inhibited by 1 μ M G-1 ( fig. 4 b) . Furthermore, 1 μ M G-1 reduced U46619-evoked spike activity also when G-1 was added to the cells before inclusion of U46619 (data not shown).
Effects of Estrogen on Ca
2+ Spike Activity in A7r5 Cells Treatment with a high physiological concentration (100 n M ) of E 2 had no effect on Ca 2+ spike amplitude and Summarized data on Ca 2+ spike amplitude ( c ) and frequency ( d ). The intracellular Ca 2+ concentration was assessed by laser scanning confocal microscopy of Fluo-4-AM-labeled cells. Summarized data are presented as means ± SEM of 4-25 observations in each group. * p < 0.05 and * * * p < 0.001, vs. control. 5 ). However, E 2 reduced Ca 2+ spike frequency, but not amplitude, at a 10 times higher concentration (1 μ M ) of E 2 ( fig. 5 ). The plasma concentration of estrogen at ovulation is about 2 n M but increases severalfold in pregnancy [24] . Thus, 100 n M E 2 is considered physiological, while 1 μ M E 2 represents a pharmacological estrogen concentration.
Downregulation of Ca 2+ Spike Activity by G-1 Is Reversed by the GPER1 Antagonist G-15 in A7r5 Cells
In order to investigate the involvement of GPER1 in G-1-induced downregulation of Ca 2+ spike activity, the GPER1 antagonist G-15 was included 10 min before G-1 inclusion and then present throughout the experiment [25, 26] . G-15 (1 μ M ) alone slightly, but not significantly, reduced Ca 2+ spike amplitude, whereas G-1 (1 μ M ) alone reduced Ca 2+ spike amplitude by about 70% ( fig. 6 ). G-1 (1 μ M ) had no effect on Ca 2+ spike amplitude in the presence of 1 μ M G-15 ( fig. 6 a, c) . In the combined presence of G-15 and G-1 (both at 1 μ M ), spiking persisted in 11 of 14 experiments, and with a higher concentration of G-15 (5 μ M ) spiking persisted in 5 of 5 experiments. In contrast, treatment with 1 μ M G-1 alone fully inhibited Ca 2+ spike activity in 11 of 17 experiments, i.e. in the presence of 1 μ M G-1 alone spiking persisted only in 6 of 17 experiments. Taken together, these data show that G-15 inhibits downregulation of Ca 2+ spike activity by G-1, suggesting that downregulation of Ca 2+ spike activity involves GPER1. fig. 7 b, d ). The L-type Ca 2+ channel blocker nifedipine (100 n M ) completely inhibited the 30 m M KCl-evoked Ca 2+ response ( fig. 7 c) . Addition of 0.1% DMSO as vehicle control had no effect on the 30 m M KClinduced rise in intracellular Ca 2+ concentration ( fig. 7 a) .
G-1 Reduces the KCl-Evoked Rise in Intracellular Ca
Discussion
Here, we investigate, using a pharmacological approach, the involvement of the putative ER GPER1 in vascular smooth muscle cell Ca 2+ handling. We show that A7r5 vascular smooth muscle cells express GPER1 mRNA. Furthermore, our results reveal that the selective GPER1 agonist G-1 acutely reduces Ca 2+ spike activity, and that this effect is blocked by the GPER1 antagonist G-15. Vascular smooth muscle A7r5 cells exhibit spontaneous, synchronous and transient rises in intracellular Ca 2+ concentration named Ca 2+ spikes [22] . Vascular smooth muscle cell Ca 2+ spike activity depends on both Ca 2+ inflow and cell-cell contact [22, 27] . In the present study, we demonstrate that G-1 reduces Ca 2+ spike activity similarly to the voltage-sensitive L-type Ca 2+ channel [27] . Addition of G-1 usually resulted in a gradual reduction in spike amplitude, which may reflect an increasing proportion of cells ceasing to fire action potentials. This could however not be analyzed due to limited spatial resolution in the present recordings on confluent A7r5 cells.
The involvement of GPER1 in the G-1-induced acute reduction in Ca 2+ spike activity was investigated using the GPER1 antagonist G-15. G-1 reduced Ca 2+ spike amplitude in the absence of G-15 but had no effect when administered in combination with G-15, suggesting that the G-1-induced reduction in Ca 2+ spike activity is mediated through GPER1. Importantly, treatment with 1 μ M G-1 alone inhibited completely Ca 2+ spike activity in 11 of 17 experiments (65%), while G-1 fully inhibited Ca 2+ spike activity in only 3 of 14 experiments (21%) in the presence of G-15, and in the presence of excess G-15 (5 μ M ), G-1 (1 μ M ) was unable to fully inhibit spike activity. Thus, G-1 seems to act through GPER1. Furthermore, we show that E 2 at 1 μ M , regarded as a pharmacological concentration of estrogen [24] , also reduces vascular smooth muscle cell Ca 2+ spike activity. This is in line with previous studies showing that E 2 , at micromolar concentrations, reduces Ca 2+ currents in cultured vascular smooth muscle cells [28] .
Previous data have suggestinged that activation of GPER1 by estrogen causes a rise in intracellular Ca 2+ concentration in GPER1-expressing COS7 cells [2] . Furthermore, intracellular injection of G-1 (3 μ M ) is reported to cause a fast and transient increase in intracellular spike activity, and that this may be a mechanism by which GPER1 controls vascular reactivity and blood pressure.
